Patents by Inventor Kiran Shambhu Toti

Kiran Shambhu Toti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE
    Publication number: 20190038627
    Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.
    Type: Application
    Filed: July 9, 2018
    Publication date: February 7, 2019
    Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
  • Methanocarba derivatives of pseudoribose that inhibit adenosine kinase
    Patent number: 10016432
    Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: July 10, 2018
    Assignees: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti
  • METHANOCARBA DERIVATIVES OF PSEUDORIBOSE THAT INHIBIT ADENOSINE KINASE
    Publication number: 20170340640
    Abstract: Adenosine kinase inhibitors, including pharmaceutical compositions containing the adenosine kinase inhibitors, and their use for preventing epilepsy and its progression in patients. The adenosine kinase inhibitors have the formula: where the moieties J and K, considered in combination, are —CH2—, or K and L, considered in combination, are —CH2—. The R1 moiety can be —NH2, C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl. The R2 and R3 moieties are each independently C1-C6 alkyl. The R4 moiety is hydrogen or C1-C6 alkyl. The R5 and R6 moieties are each independently C6-C12 aryl, C3-C8 cycloalkyl, or C3-C8 heteroaryl, that is optionally further substituted.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicants: Legacy Emanuel Hospital & Health Center, The United States of America, as represented by The Secretary, Department of Health and Human Serv
    Inventors: Kenneth Alan Jacobson, Detlev Boison, Kiran Shambhu Toti